财经快讯|双鹭药业：抗过敏药地氯雷他定已提交上市申请即将获批上市
双鹭药业4月28日在互动平台表示，公司氯雷他定分散片系抗过敏药，因之前未进入集采，目前销量较小，一季度仅有几十万，但近期过敏患者剧增，该产品销量也呈快速增长。公司另一抗过敏药地氯雷他定也已提交上市申请即将获批上市。
Statement:
The content of this article does not represent the views of fxgecko website. The content is for reference only and does not constitute investment suggestions. Investment is risky, so you should be careful in your choice! If it involves content, copyright and other issues, please contact us and we will make adjustments at the first time!
Related News
